Key facts
- Vergent Bioscience’s last known valuation is $75.0M (Oct 2025).
- It has raised $56.4M across 5 recorded rounds; the latest was Early Stage VC ($18.7M) in Oct 2025.
- Notable investors include National Institutes of Health, Spring Mountain Capital, Colle Capital Partners, Intuitive Surgical, Orlando Health Ventures — 7 tracked in total.
- Vergent Bioscience has filed 7 Form Ds with the SEC since 2018, most recently Feb 2025 ($3.8M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Vergent Bioscience
Funding rounds
5 roundsAbout Vergent Bioscience
Developer of molecular imaging probes designed for the diagnosis and removal of cancer cells. The company develops molecularly-targeted probes that bind to enzymes that are over-expressed in tumor tissue, activating a brightly fluorescing dye when injected before surgery, enabling surgeons to locate and completely remove tumors during resection surgery through improved visual clarity.
- Sector
- Healthcare
- HQ
- Minneapolis, MN, United States
- Founded
- 2013
- Employees
- 10
- Website
- vergentbio.com/
- Ownership
- Privately Held (backing)
Vergent Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vergent Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vergent Bioscience in its N-PORT filings yet. We sweep new filings monthly.